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SUV39H1/H3K9me3 attenuates sulforaphane-induced
apoptotic signaling in PC3 prostate cancer cells
GW Watson1,2, S Wickramasekara3, Z Palomera-Sanchez2, C Black2, CS Maier3, DE Williams4,5, RH Dashwood4,6 and E Ho1,2,5
The isothiocyanate sulforaphane is a promising molecule for development as a therapeutic agent for patients with metastatic
prostate cancer. Sulforaphane induces apoptosis in advanced prostate cancer cells, slows disease progression in vivo and is well
tolerated at pharmacological doses. However, the underlying mechanism(s) responsible for cancer suppression remain to be fully
elucidated. In this investigation we demonstrate that sulforaphane induces posttranslational modification of histone
methyltransferase SUV39H1 in metastatic, androgen receptor-negative PC3 prostate cancer cells. Sulforaphane stimulates
ubiquitination and acetylation of SUV39H1 within a C-terminal nuclear localization signal peptide motif and coincides with its
dissociation from chromatin and a decrease in global trimethyl-histone H3 lysine 9 (H3K9me3) levels. Exogenous SUV39H1
expression leads to an increase in H3K9me3 and decreases sulforaphane-induced apoptotic signaling. SUV39H1 is thus identified as
a novel mediator of sulforaphane cytotoxicity in PC3 cells. Our results also suggest SUV39H1 dynamics as a new therapeutic target
in advanced prostate cancers.
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INTRODUCTION
Prostate cancer is one of the most commonly diagnosed cancers
in the United States, the incidence of which is expected to
increase as the population ages. Several treatment strategies have
been developed for prostate cancer therapy, including surgical
removal of the prostate, radiation therapy, hormone or androgen
deprivation therapy and chemotherapy. A majority of cases
initially respond to frontline treatments; however, despite best
efforts, resistant clones arise to resume growth and seed distal
sites with metastatic tumors.1 Once this occurs, survival rates
decrease dramatically and treatment options are limited.
Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) is an
isothiocyanate derived from cruciferous vegetables that is known
to possess cancer-suppressive activity.2 The compound is well
tolerated and is cytotoxic specifically toward transformed cells,
inducing cell cycle arrest and apoptosis. Although differences in
sensitivity between cell lines do exist, the tissue of origin or
genetic profile does not appear to be determinant: sulforaphane is
cytotoxic to many human cancer cell lines in vitro, including
prostate,3 breast,4 ovarian,5,6 colon7 and pancreatic cancers,8 and
can suppress cancer progression in genetic models of colon9 and
prostate10 carcinoma. Sulforaphane has been shown to (i) induce
cell death in metastatic prostate cancer cell lines while sparing
primary prostate epithelial cells,3 (ii) decrease metastases in a
genetically engineered mouse model of prostate cancer10 and
(iii) is not associated with adverse effects when administered at
pharmacological doses in rodents.11 These observations make
sulforaphane a compound of interest for development as a
prostate cancer therapeutic agent.
Several investigations have characterized broad alterations in
the epigenome in prostate cancer patients and suggested that
epigenetic profile and expression levels of chromatin-modifying
enzymes (CMEs) have some prognostic value.12–15 Progressive
dysregulation of the epigenome as cells adopt a malignant
phenotype is now recognized as an active contributor to
transformation that works in tandem with genetic alterations to
allow cancer progression. As epigenetic state is reversible,
targeting the epigenome is an attractive therapeutic strategy.
Indeed, a number of small molecule inhibitors targeting CMEs
are approved or are in clinical and preclinical trials as
chemotherapeutic agents.16 Recent investigations characterizing
sulforaphane-induced changes in the level and activity of CMEs
has led to the hypothesis that modulation of these enzymes
contributes to cell cycle arrest and apoptosis in prostate cancer
cells. Sulforaphane leads to a decrease in global histone
deacetylase (HDAC) activity in prostate cancer cells through
depletion of specific HDAC isoforms.3 Sulforaphane has also been
shown to decrease DNA methyltransferase (DNMT) levels in
prostate cancer cells.17 Little is known concerning the effects of
sulforaphane on histone methylation—only one investigation has
characterized an influence on histone H3 lysine 27 trimethylation
(Balasubramanian et al.18)—despite the fact that DNMT, HDAC
and histone methyltransferases (HMT) and demethylases (HDM)
physically interact and work cooperatively in larger protein
complexes to maintain or alter chromatin structure.19–21 Further-
more, any postulated heterochromatin-dependent contribution of
HDAC or DNMT depletion is likely secondary to changes in histone
methylation, as DNMT functions downstream of HMTs and HDAC
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enzymes lack protein domains that can independently recognize
chromatin.22–24 This led us to investigate whether changes in
global histone methylation accompany changes in CME protein
level and activity in sulforaphane-treated prostate cancer cells. As
HDAC and DNMT enzymes facilitate heterochromatin formation
and stabilization, and sulforaphane depletes these proteins in
prostate cancer cells, we hypothesized a decrease in histone
methyl marks associated with heterochromatin in sulforaphane-
treated prostate cancer cells.
Histone methylation is more complex than the chromatin marks
controlled by HDAC (acetylation) and DNMT (DNA methylation)
enzymes. As opposed to existing in one of two states, each
with a characteristic association with chromatin structure, the
outcome of histone methylation is residue- and mark-specific
(see Martin and Zhang25 and references therein for summary).
We focused our investigation on the archetypal heterochromatin
mark trimethyl-histone H3 lysine 9 (H3K9me3) and conducted our
mechanistic investigation in PC3 cells, a culture model of
metastatic, aggressive, androgen receptor-negative prostate
cancer. PC3 cells are an advantageous prostate cancer cell line
to test our hypothesis, because sulforaphane depletes HDAC3 and
DNMT17 enzymes in these cells and the H3K9me3 mark is
controlled by one HMT, SUV39H1, with no functional
redundancy.26 Here we present evidence supporting a model
where a decrease in H3K9me3 mediated by posttranslational
regulation of SUV39H1 enhances apoptotic signaling in
PC3 cells in response to sulforaphane, suggesting indirect
inhibition or destabilization of SUV39H1 as a potential treatment
strategy.
RESULTS
Sulforaphane decreases global trimethyl H3K9 levels
Sulforaphane treatment leads to a global decrease in H3K9me3 in
PC3 cells (Figure 1). The decrease was detectable as early as 6 h
post treatment and remained at a depressed level through 12 h.
At 24 h, H3K9me3 returned to control levels (not shown). An
assessment of H3K9me3 level in sulforaphane-treated LNCaP and
DU145 metastatic prostate cancer cell lines showed no global
response (not shown).
Sulforaphane has previously been shown to induce G2/M arrest
in PC3 cells,27 and H3K9me3 levels have recently been found to
fluctuate with the cell cycle, increasing at the centromere through
metaphase before reaching a peak and declining through
anaphase.28 The global decrease in H3K9me3 we observed
following sulforaphane treatment suggests that large blocks of
chromatin, possibly megabases in length, are undergoing
H3K9me3 depletion, which would be consistent with alterations
in centromeric H3K9me3 levels. This raises the possibility that a
global decrease in H3K9me3 in sulforaphane-treated cells is an
artifact of cell cycle arrest and not depletion of heterochromatic
CMEs per se. Cyclin B1 protein level was therefore analyzed to
assess the possibility of a cell cycle effect. An analysis of cyclin B1
protein level (Supplementary Figure 1), known to accumulate in
metaphase-arrested PC3 cells,29 showed no difference between
treatment groups within our treatment period of interest,
suggesting the decrease in H3K9me3 is independent of cell cycle
and not a consequence of arrest. Visualization of 4,6-diamidino-2-
phenylindole (DAPI)-stained sulforaphane-treated nuclei also
indicated arrest before metaphase (not shown).
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Figure 1. (a) Sulforaphane causes a global decrease in H3K9-trimethylation in PC3 cells. H3K9me3 was decreased relative to global histone H3
at 6 and 12 h post treatment (Po0.01 by two-way analysis of variance (ANOVA) with Bonferroni post test, mean+s.e.m. for three independent
experiments). (b) Representative blot from one of three independent experiments at 12 h post treatment. (c) SUV39H1 is increased at 6 h post
treatment (Po0.05 by two-way ANOVA with Bonferroni post test, mean+s.e.m. for three independent experiments). The early increase in
SUV39H1 was not maintained, with the protein returning to control level by 12 h. (d) Representative blots from one of three independent
experiments at 12 h post treatment. β-Actin was probed as a loading control. SFN, sulforaphane.
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Sulforaphane does not affect the protein level of H3K9 methyl
modifiers
H3K9 methylation is controlled by multiple HMTs and HDMs, with
several enzymes capable of catalyzing specific modifications. A
decrease in global H3K9me3 levels could be caused by a decrease
in HMT activity, an increase in HDM activity, or some combination
of the two. SUV39H methyltransferase proteins (specifically
isoform 1) control H3K9me3 at pericentromeric and centromeric
chromatin domains,30 suggesting depletion or inactivation of
SUV39H1 could account for the global decrease in H3K9me3 we
observed by western blotting. Furthermore, targeted knockdown
of SUV39H1 by small interfering RNA in PC3 cells leads to a global
decrease in H3K9me3 and has a minimal effect on global gene
expression,26 suggesting SUV39H1 is solely responsible for H3K9
trimethylation with little or no functional redundancy and that
SUV39H1-specific effects are independent of gene promoter
regulation. We observed a transient increase in SUV39H1 in
sulforaphane-treated cells and no change in SUV39H2 protein
level over the treatment period (Figure 1).
HDM enzymes are a relatively recent discovery and less is
known about their role in genome maintenance; we nevertheless
assessed the protein level of several HDMs known to have activity
toward H3K9 (Kondo31). No significant increase in the level of
HDM LSD1 (KDM1A), JMJD1A (KDM3A) or JMJD2C (KDM4C) was
maintained over the 12-h treatment period (Figure 2).
No sustained change in the protein level of the enzymes that
control H3K9 methylation suggests regulation through a post-
translational mechanism. We focused our investigation on
SUV39H1, as it can influence global H3K9me3 and is known to
physically interact with HDAC and DNMT enzymes.32,33 We
hypothesized an increase in posttranslational modifications
associated with decreased SUV39H1 activity or stability in
response to sulforaphane.
Sulforaphane leads to SUV39H1 posttranslational modification
SUV39H1 is known to be regulated posttranslationally: the protein
is subject to phosphorylation,30 acetylation,34 ubiquitination35 and
methylation,36 all of which have been associated with changes in
localization or decreased stability and activity. Discrete lysine
residues on SUV39H1 have been characterized as subject to
posttranslational modification. Acetylation of lysine 266 has been
shown to inhibit catalytic activity34 and ubiquitination of lysine 87
has been shown to facilitate degradation.35 We used liquid
chromatography-coupled tandem mass spectrometry (LC-MS/MS)
to assess sulforaphane-induced posttranslational modifications of
endogenous SUV39H1 protein in PC3 cells (Figure 3 and
Supplementary Figure 2). We identified ubiquitinated (ub-K393-
SUV39H1) and acetylated SUV39H1 (ac-K394-SUV39H1) only in
sulforaphane-treated cells on an overlapping C-terminal peptide
(379-MDSNFGLAGLPGSPKKRVR-397). Ubiquitinated SUV39H1
(ub-SUV39H1) was confirmed by immunoprecipitation (Figure 4).
Increased ub-SUV39H1 occurred despite a global decrease in
ubiquitinated proteins.
Sirtuin 1 (SirT1) is reported to control SUV39H1 ubiquitination
and acetylation,35 suggesting SUV39H1 modification may be the
result of sulforaphane-induced changes in the protein level or
activity of SirT1. Sulforaphane has been found to influence the
protein level of some Sirtuins in colon cancer cells.37 We did not
observe a hypothesized decrease in SirT1 protein level that would
explain SUV39H1 destabilization or inhibition in sulforaphane-
treated PC3 cells (Figure 5). A test of direct inhibition of SirT1
catalytic activity by the intracellular metabolites of sulforaphane
at relevant intracellular concentration3,38,39 also revealed no
activity as a direct inhibitor (Figure 5). These data suggest
SirT1-independent posttranslational control of SUV39H1 protein.
Sulforaphane leads to a decrease in chromatin-associated
SUV39H1
The effects of lysine 393 or 394 modification are not known, but
these residues fall within a predicted nuclear localization signal
peptide motif (391-SPKKRVRIE-399) (predicted by three indepen-
dent motif recognition tools;40–42 Supplementary Figure 3). This
led us to hypothesize that modification of these residues would be
associated with a change in SUV39H1 localization. Visualization by
immunofluorescence revealed discrete nuclear foci characteristic
of chromatin-associated SUV39H1. A separate pool of mobile
SUV39H1 was also identified in the perinuclear cytoplasmic region
and spread diffusely within the nucleus (Figure 6c). Quantification
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Figure 2. (a) Sulforaphane does not significantly alter the global level of selected H3K9 demethylases, although the expression is highly
variable in PC3 cells (12 h blot pictured). No change in (b) LSD1 (KDM1A), (c) JMJD1A (KDM3A) or (d) JMJD2C (KDM4C) was noted in
sulforaphane-treated cells (two-way analysis of variance with Bonferroni post test, mean+s.d.). SFN, sulforaphane.
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by western blotting showed an increase in cytoplasmic (or mobile)
SUV39H1 and a decrease in nuclear (or immobile, histone
associated) SUV39H1 in sulforaphane-treated cells (Figure 6).
Exogenous expression of SUV39H1 decreases sulforaphane-
induced apoptotic signaling
SUV39H1 modification, altered localization and decreased global
H3K9me3 levels in sulforaphane-treated PC3 cells suggests that
SUV39H1 and/or H3K9me3 depletion may have a role in
sulforaphane-induced cytotoxicity.3,43 To test whether SUV39H1
or global H3K9me3 contribute to sulforaphane-triggered apopto-
sis in PC3 cells, we overexpressed SUV39H1 by transient
transfection to increase H3K9me3, then treated with sulforaphane
and monitored cleaved poly-ADP ribose polymerase—a terminal
cleavage event in apoptotic signaling—to assess changes in
cytotoxicity (Figure 7 and Supplementary Figure 4). Exogenous
Figure 3. Identification of ubiquitinated and acetylated lysine residues on SUV39H1 in sulforaphane-treated PC3 cells. (a) a, y and b ion peptide
coverage by liquid chromatography–tandem mass spectrometry (LC-MS/MS) of the C-terminal peptide 379-MDSNFGLAGLPGSPKKRVR-397 in
control-treated (dimethyl sulfoxide (DMSO)) (left) and sulforaphane-treated (right) cell lysate. Coverage corresponds to asterisked peptides
in b. (b) Peptides and modifications of the C-terminal region. The C-terminal region of interest is phosphorylated (P) and methylated (M) in both
DMSO control and sulforaphane-treated lysates. Ubiquitinated (Ub) and acetylated (Ac) lysines were only identified in sulforaphane-treated cells.
Spectra for the asterisked peptides in b can be found in Supplementary Figure 2.
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Figure 4. (a) PC3 cells were co-treated with MG132 (10 μM) and dimethyl sulfoxide (DMSO) or sulforaphane for 9 h. Ubiquitinated proteins were
immunoprecipitated from lysates and subsequently analyzed for SUV39H1 protein. An increase in ubiquitinated SUV39H1 was noted in
sulforaphane-treated cells. The increase in high-molecular weight SUV39H1 occurred despite a global decrease in ubiquitinated protein levels.
Untreated PC3 lysate (Ntx) was immunoprecipitated with normal IgG and analyzed in parallel as a control. (b) The reverse
immunoprecipitation (SUV39H1 immunoprecipitation→ ubiquitin analysis) under the same experimental conditions as in a confirmed
increased ubiquitinated SUV39H1 in sulforaphane-treated cells. SFN, sulforaphane.
Sulforaphane influences SUV39H1/H3K9me3
GW Watson et al
4
Oncogenesis (2014), 1 – 9
SUV39H1 expression (SUV) increased global H3K9me3 levels
relative to control (GFP (green fluorescent protein)) and sulfor-
aphane did stimulate apoptotic signaling as measured by cleaved
poly-ADP ribose polymerase. We noted a decrease in cleaved
poly-ADP ribose polymerase in SUV39H1-overexpressing cells in
response to sulforaphane relative to GFP-control, suggesting
SUV39H1/H3K9me3 is protective against sulforaphane-induced
cytotoxicity and that a global decrease in H3K9me3 contributes to
cell death in PC3 cells.
DISCUSSION
In this investigation we characterized a novel response to the
natural compound sulforaphane in PC3 prostate cancer cells
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Figure 5. (a) Sulforaphane does not affect SirT1 protein level at 6 or 12 h post treatment. Sample blot from 12-h time point pictured (two-way
analysis of variance with Bonferroni post test, mean+s.d.). (b) Intracellular sulforaphane metabolites do not directly inhibit or activate SirT1
catalytic activity (Student’s t-test, mean+s.d.). RFU, relative fluorescence units; Sirt1, basal enzyme activity; NC, negative control (nicotinamide
solution); PC, positive control (resveratrol); Blank, no enzyme; SFN-GSH, sulforaphane-glutathione (1 mM); SFN-Cys, sulforaphane-cysteine
(150 μM).
DMSO SFN
Ub
SU
V3
9H
1
SU
V3
9H
1 
+ 
DA
PI
 N
uc
le
ar
 S
ta
in
Nuclear                                  
(chromatin associated)                   
DMSO     SFN        DMSO     SFN         
SUV39H1
fibrillarin
tubulin
actin
SUV39H1 Protein1.5
1.0
0.5
0.0
R
el
at
iv
e 
Pr
o
te
in
Chrom. Assc. Mobile
DMSO
SFN**
*
a b
c
Cytoplasmic
(mobile)
Figure 6. (a) Representative image of control (dimethyl sulfoxide (DMSO)) and sulforaphane-treated (12 h) PC3 cells with nuclear
(4,6-diamidino-2-phenylindole (DAPI)) and SUV39H1 labeling for immunofluorescent imaging. The chromatin-associated SUV39H1 foci and
dispersed nuclear and perinuclear mobile fractions are readily visible. (b) Sulforaphane leads to a decrease in chromatin-associated SUV39H1.
PC3 cells were treated for 8 h with sulforaphane. MG132 was spiked into the culture dishes at a final concentration of 50 μM for the last 2 h of
the treatment. The high-dose, short-duration treatment was to halt a sulforaphane-stimulated increase in proteasome activity and decrease
the impact of any MG132 toxicity. The experimental conditions did inhibit protein degradation (increase in ubiquitinated proteins in
sulforaphane-treated PC3 cells). (c) Densitometry showed a decrease in histone-associated SUV39H1 and an increase in mobile SUV39H1
(*Po0.05, **Po0.01 by two-way analysis of variance with Bonferroni post test, mean+s.d.). Histone-associated (nuclear, immobile) SUV39H1
normalized to nuclear marker fibrillarin. Mobile (cytoplasmic) SUV39H1 normalized to β-actin. SFN, sulforaphane.
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involving the histone modifier SUV39H1. We present evidence
supporting a model where sulforaphane-induced posttranslational
modification of SUV39H1 decreases the chromatin-associated
cellular fraction, leading to a decrease in H3K9me3 (Figures 1, 3, 4
and 6). We go on to show that SUV39H1/H3K9me3 decreases
apoptotic signaling in PC3 cells (Figure 7), suggesting the changes
in SUV39H1 dynamics in sulforaphane-treated PC3 cells contribute
to cytotoxicity. Taken together, these results suggest that
posttranslational modification of SUV39H1 may be a promising
therapeutic strategy in the treatment of advanced prostate cancer.
Perturbations in SUV39H1 protein level in normal cells is known
to increase cancer risk: engineered mice that are SUV39H-null
show an increased susceptibility to cancer44 and mice that
overexpress SUV39H1 show defects in cell differentiation and
proliferation that can result in chronic myeloid leukemia.45
SUV39H1 can also influence metastatic potential in transformed
cells: a potentially chromatin-independent role for SUV39H1 in
facilitating cell motility and invasion has recently been character-
ized in hepatocellular carcinoma cells.46 SUV39H1 knockdown
specifically in PC3 cells also supports a gene expression-
independent role in cell proliferation.26 Chemotherapeutic strate-
gies pursuing direct SUV39H1 inhibition are being investigated,
although the in vivo activity of the leading candidate, chaetocin, is
debatable.47–50 Our data suggests an alternative strategy for
targeting SUV39H1 involving indirect destabilization or modula-
tion of the posttranslational modifiers that regulate SUV39H1,
several of which have been characterized.34,35 Small molecule
modulators are currently being tested that target such proteins
(for example, MDM2 inhibitors51), yet the contribution, if any, of
SUV39H1-modification to the activity of these molecules is not
known. Assessing this possible contribution will be important to
gain a complete understanding of how and why such molecules
are effective agents.
Although sulforaphane is known to induce cellular stress and
general protein turnover through the ubiquitin-proteasome
pathway52 and induction of the autophagic pathway,53 the data
presented here suggests that sulforaphane leads to directed
SUV39H1 modification in PC3 cells. We observed an increase in
ubiquitinated SUV39H1, despite a global decrease in ubiquitinated
proteins in sulforaphane-treated cells (Figure 4), suggesting
controlled regulation as opposed to general turnover. We also
noted no significant increase in SUV39H1 protein level in
SUV39H1-overexpressing PC3 cells, despite a global increase in
H3K9me3 (Figure 7). The finding that global H3K9me3 levels are
not affected in sulforaphane-treated LNCaP and DU145 cells also
suggests directed regulation in response to sulforaphane in PC3
cells. Further work will be needed to identify the factors
accounting for the differential response between cell lines and
will be important in developing a genetic signature of the subset
of advanced prostate cancers that would be susceptible
to exploiting modulation of SUV39H1 dynamics to enhance
apoptotic signaling.
An increase in global H3K9me3 levels in SUV39H1-transfected
cells with no corresponding increase in SUV39H1 protein level
(Figure 7) suggests SUV39H1 protein level is tightly regulated in
PC3 cells through posttranslational control, and that SUV39H1
dynamics are what determine global H3K9me3. Taken together
with the shift in SUV39H1 pools from chromatin associated to
mobile in sulforaphane-treated cells (Figure 6), these data suggest
a model where SUV39H1 rate-of-renewal at heterochromatic sites
is the parameter affected by sulforaphane-induced modification.
The increase in cytoplasmic (or mobile) SUV39H1 should therefore
be interpreted as a delayed renewal time at chromatin, which we
propose to be a consequence of modification of a conserved
nuclear localization signal. An alternative hypothesis could
propose decreased enzymatic activity through interference with
conserved putative zinc-coordinating cysteines in the adjacent
post-SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain
(Supplementary Figure 3). Mutagenesis studies have shown these
cysteines to be required for enzymatic activity in other post-SET
domain-containing H3K9 methyltransferases.54 However, given
the rather modest decrease in global H3K9me3 in sulforaphane-
treated cells compared with catalytically impaired SUV39H1
mutants,35,55,56 inhibition of SUV39H1 activity is less likely. This
interpretation is also in agreement with a recent report by Park
et al.57 where they characterized CDK2-dependent phosphoryla-
tion of SUV39H1 at lysine 391, a mark we identified in
sulforaphane-treated PC3 lysate by mass spectrometry
(Figure 3). Mutagenesis at lysine 391 to mimic phosphorylation
did not alter enzymatic activity, but did influence occupancy at
heterochromatin and led to a decrease in H3K9me3 at specific
repeat elements. This supports our model proposing that
modification of this region leads to decreased H3K9me3 through
a shift from chromatin-associated to mobile SUV39H1 and not
through impaired enzymatic activity.
This is the first investigation to characterize changes in
SUV39H1/H3K9me3 in the response to sulforaphane in any cell
type. Although SUV39H1 turnover rate and recovery time have
been shown to have a significant impact on global H3K9me3 and
genome stability,35 the impact in the context of sulforaphane
treatment is not known. We found that increased H3K9me3 in
SUV39H1-transfected cells associated with decreased apoptotic
signaling (Figure 7), indicating that H3K9me3 is protective in
sulforaphane-treated PC3 cells and suggesting that modulation of
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Figure 7. SUV39H1 decreases cleaved poly-ADP ribose polymerase
(cPARP) in sulforaphane-treated PC3 cells. PC3 cells were transfected
with GFP (control) or SUV39H1 (SUV) expression vector and allowed
to recover for 36 h. Cells were incubated with sulforaphane for 24 h
before collecting whole-cell lysates. H3K9me3 is increased in
SUV39H1-transfected PC3 cells (SUV: dimethyl sulfoxide (DMSO),
SUV:SFN) relative to GFP control (GFP:DMSO, GFP:SFN) (normalized
to histone H3), although no increase in total SUV39H1 protein was
noted (normalized to β-actin). Sulforaphane treatment significantly
increased apoptotic signaling as assessed by cPARP in GFP- and
SUV39H1-transfected cells. SUV39H1 overexpression significantly
decreased cPARP protein levels, indicating decreased apoptotic
signaling (*Po0.05, **Po0.01 by one-way analysis of variance with
Bonferroni post test for each protein, mean+s.e.m. for two
independent experiments; blot from representative experiment
pictured).
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this methyl mark and modifier actively contributes to sulfora-
phane cytotoxicity.
An important aspect of our investigation is the characterization
of SUV39H1 modification within 12 h of sulforaphane treatment.
Sulforaphane is rapidly metabolized and excreted from the
body.58,59 Even when administered intravenously at a pharmaco-
logical dose to achieve ~ 15 μM plasma concentration in a rat
model, the majority of sulforaphane and its metabolites are
cleared in less than 12 h.11 Our treatment periods exist within the
pharmacokinetic parameters of sulforaphane metabolism in vivo,
suggesting our results may be achievable in a clinical setting.
Here we implicated a new chromatin mark and CME in the
cellular response to sulforaphane in PC3 prostate cancer cells. We
propose a model where sulforaphane causes a decrease in
H3K9me3 through posttranslational modification of H3K9 methyl-
transferase SUV39H1, and that this actively contributes to
sulforaphane-induced apoptotic signaling. These findings suggest
that targeting SUV39H1 dynamics to enhance cell death signaling
may be a strategy worth exploring in treating advanced metastatic
cancers.
MATERIALS AND METHODS
Cells and reagents
Prostate cancer cells (PC3 and LNCaP) were purchased from American Type
Culture Collection (Manassas, VA, USA) or received as a gift (DU145 line
from Dr Philippe T Georgel, Marshall University). Cells were maintained in
RPMI-1640 media with L-glutamine supplemented with fetal bovine serum
(50ml fetal bovine serum/500ml media) at 37 °C 5% CO2. PC3 and LNCaP
cell lines were validated by Idexx Radil (Columbia, MO, USA) on 24
December 2012. Sulforaphane was purchased from LKT Laboratories
(St Paul, MN, USA). Sulforaphane-glutathione and sulforaphane-cysteine
were purchased from Toronto Research Chemicals (Toronto, ON, Canada).
MG132 was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Primary antibodies against ubiquitin (Santa Cruz Biotechnology), SUV39H2
(Santa Cruz Biotechnology), SUV39H1 (Santa Cruz Biotechnology, Millipore
(Billerica, MA, USA)), SirT1 (eBioscience, San Diego, CA, USA), β-actin
(Sigma, Saint Louis, MO, USA), trimethyl histone H3 lysine 9 (Millipore),
cleaved poly-ADP ribose polymerase (Cell Signaling, Danvers, MA, USA),
cyclin B1 (Cell Signaling), fibrillarin (Cell Signaling), LSD1 (Abcam,
Cambridge, MA, USA), JMJD1A (Abcam), JMJD2C (Abcam), α-tubulin
(Sigma) and histone H3 (Bethyl, Montgomery, TX, USA), and horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz) were used in
accordance with the manufacturer’s protocol. SirT1 Activity Assay was
conducted in accordance with the manufacturer’s protocol (Sigma).
Sulforaphane-cysteine and sulforaphane-glutathione conjugates were
produced in house. Liquid chromatography–MS grade solvents were
purchased from Millipore. Subconfluent cells were treated with control
(dimethyl sulfoxide), sulforaphane (15 μM) and/or MG132 (at the indicated
dose) and incubated at 37 °C 5% CO2 until collection.
Protein analysis
Protein lysates were prepared in RIPA protein lysis buffer (150mM NaCl, 1%
Triton X-100, 0.5% NaDOC, 0.1% SDS, 20 mM Tris pH 8.0) supplemented
with protease inhibitor cocktail (Thermo, Waltham, MA, USA) followed by
sonication in an ice-cold waterbath. Lysates were cleared by centrifugation
at 4 °C and quantitated by DCA Protein Assay (BioRad, Hercules, CA, USA).
For SUV39H1 localization, cells were incubated in 0.5% Triton X-100
phosphate-buffered saline with protease inhibitor cocktail for 15 min on
ice. Cells were then vortexed and nuclei spun out. Nuclei were washed in
phosphate-buffered saline and resuspended in RIPA lysis buffer and
incubated on ice for 10min. Lysates were then subjected to sonication in
an ice-cold waterbath.
Proteins were separated by SDS–polyacrylamide gel electrophoresis and
blotted to a polyvinylidene difluoride membrane (BioRad) using NuPAGE
Reagents and equipment in accordance with the manufacturer’s protocols
(Invitrogen, Carlsbad, CA, USA). Membranes were blocked and probed for
proteins of interest following manufacturer’s protocols. Membranes were
incubated in SuperSignal West Femto Reagent (Thermo) and developed on
the AlphaInnotech FluorChem 8900 system (ProteinSimple, San Jose, CA,
USA). Membranes were stripped using ReBlot Plus Strong Solution as
needed in accordance with the manufacturer’s protocol (Millipore).
Densitometric analyses were performed on the native membrane image
using AlphaInnotech FluorChem 8900 software. For each membrane, the
relative densitometric value of each replicate for a given probe was
normalized to the corresponding relative level of the normalizing protein.
For graphing, treatments are expressed relative to Control (set to the value
1). Proteins are normalized to β-actin unless otherwise indicated.
Immunoprecipitation
Lysates were prepared by one freeze–thaw in non-denaturing lysis buffer
(137mM NaCl, 1% Triton X-100, 2 mM EDTA, 20mM Tris pH 8.0), cleared by
centrifugation and quantitated by DCA Protein Assay (BioRad). Equal
protein lysate (2–3mg) was incubated with primary antibody (anti-
ubiquitin or anti-SUV39H1) overnight at 4 °C, then with Protein A agarose
(Sigma) or Protein A/G PLUS agarose (Santa Cruz) for 2–4 h at 4 °C.
Immunoprecipitates were washed three to five times in non-denaturing
lysis buffer and eluted in 2% SDS TBS (Tris-buffered saline) at room
temperature for 15min.
Immunofluorescence
Immunofluorescence was carried out following standard protocols. Briefly,
PC3 cells were grown and treated on glass coverslips. Cells were fixed in 100%
methanol and then in 4% paraformaldehyde. Fixed cells were permeabilized
in 0.4% Triton X-100 phosphate-buffered saline and blocked in 5% bovine
serum albumin 0.1% NP-40 phosphate-buffered saline. Cells were probed
with SUV39H1 antibody (Santa Cruz), followed by incubation in anti-rabbit
Alexa Fluor-555 (Invitrogen) and finally with 4,6-diamidino-2-phenylindole
(Millipore). Coverslips were mounted on glass slides using ProLong Gold
Antifade Reagent (Invitrogen) and images captured on a Nikon Eclipse E400
microscope using Nikon NIS-Elements software (Nikon, Tokyo, Japan).
Mass spectrometry
PC3 cells were washed twice in 50mM sodium bicarbonate and subjected
to one freeze–thaw at − 80 °C in 50mM sodium bicarbonate. Liberated
proteins were separated from cellular debris by centrifugation at 13 000 r.p.
m. for 10min at 4 °C. Proteins were reduced, alkylated and digested using
Trypsin Gold in presence of ProteaseMax surfactant according to the
manufacturer’s protocols (Promega, Madison, WI, USA).
Liquid chromatography–MS/MS analysis was carried out using a
nanoAcquity UPLC system (Waters Corporation, Milford, MA, USA) coupled
to an LTQ-FT MS instrument (Thermo Fisher Scientific, San Jose, CA, USA).
A binary solvent system consisting of solvent A (water with 0.1% formic
acid) and solvent B (acetonitrile with 0.1% formic acid) was used for the
analyses. Tryptic peptides (2 μl) were loaded onto a peptide trapping
column (Michrom Cap Trap; Bruker Daltonics Inc., Billerica, MA, USA) and
separated using a C18 analytical column (Agilent Zorbax 300SB-C18 (Santa
Clara, CA, USA), 250 × 0.3 mm, 5 μm). Peptides were trapped and washed
with 3% solvent B for 3 min at a flow rate of 5 μl/min. Peptide separation
was achieved using a linear gradient from 10% to 30% B at a flow rate of
4 μl/min over 102min. The LTQ-FT mass spectrometer was controlled by
Xcaliber 2.0 (Thermo Fisher Scientific) and operated in data-dependent
MS/MS acquisition with MS precursor ion scan, performed in the ion
cyclotron resonance (ICR) cell, from 350–2000m/z. Instrument resolving
power was set to 100 000 at m/z 400, and MS/MS scans were performed by
the linear ion trap on the five most abundant doubly or triply charged
precursor ions detected in the MS scan.
Thermo RAW data files were processed with Mascot database analysis
software (v2.3) (Matrix Science, Boston, MA, USA) within Proteome
Discoverer v1.4.0 (Thermo). Data files were searched against the Human
protein RefSeq database downloaded from NCBI (http://www.ncbi.nlm.nih.
gov/protein) and to an in-house database containing SUV39H1 protein
sequence (NP_003164.1) and decoy protein sequences including common
contaminants.
The following parameters were used to search the database: the
digestion enzyme was set to Trypsin and three missed cleavage sites were
allowed. The precursor ion mass tolerance was set to 20 p.p.m. and the
fragment ion tolerance was set to 1.0 Da. Dynamic modifications that were
considered included carbamidomethyl-cysteine (+57.02 Da), oxidated
methionine (+15.99 Da), deamidated asparagine or glutamine (+0.98 Da),
phospho-serine, -threonine, or -tyrosine (+97.98 Da), ubiquitinated lysine
(+114.04 Da), methyl-lysine (+14.02) and acetyl-lysine (+42.01 Da). Auto-
matic target decoy search with 1% false discovery rate was included into
the Mascot search. Scaffold_3.3.1 (Proteome Software, Portland, OR, USA)
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was used for search data compilation and data evaluation with an
embedded X!Tandem database searching algorithm. Protein identifications
were accepted if they could be established at > 90% probability and
contained at least 2 identified peptides per protein with a false discovery
rate o5%. Assigned spectra were inspected manually for quality. Spectra
assigned to both databases (Human RefSeq and in-house DB) were
manually assigned using custom python scripts and the best match
selected.
Quantitative real-time PCR
Total RNA was collected by TRIzol reagent in accordance with the
manufacturer’s protocol (Invitrogen). cDNA was prepared from μg RNA
using the SuperScript III kit from Invitrogen. Approximately 50 ng cDNA
was amplified by Fast SYBR Green Reagent in accordance with the
manufacturer’s protocol (Invitrogen) on a 7900HT Real Time PCR Machine
(Applied Biosciences, Life Technologies, Carlsbad, CA, USA).
Primers used were as follows: glyceraldehyde 3-phosphate dehydro-
genase (sense 5′-CGAGATCCCTCCAAAATCAA-3′, antisense 5′-TTCACACC
CATGACGAACAT-3′); HO1 (sense 5′-CTTCTTCACCTTCCCCAAC-3′, antisense
5′-GCTCTGGTCCTTGGTGTCATA-3′); SUV39H1 (sense 5′-GCTAGGCCCGAATG
TCGTTA-3′, antisense 5′-GCCTTCTGCACCAGGTAGTT-3′).
SUV39H1 cloning
SUV39H1 coding sequence was amplified from PC3 cDNA using primers to
append a 5′ EcoRI and 3′ NotI restriction site (sense 5′-CTGCCGCC
GAATTCCCCGAATGTCGTTAGCCGTGGGGAAAG-3′, antisense 5′-ATCTGAG
AGCGGCCGCCACGGCCACAGCCCTGAACG-3′). SUV39H1 coding sequence
was digested and ligated into pCMV6-AC-GFP destination vector (Origene,
Rockville, MD, USA). The ligation mixture was transformed into One Shot
TOP10 Chemically Competent Escherichia coli following the manufacturer’s
protocol (Invitrogen). Plasmid was isolated using the QIAprep Spin
Miniprep Kit (Qiagen, Venlo, Netherlands). Candidates were screened for
insert using SUV39H1 primers (sense 5′-GCTAGGCCCGAATGTCGTTA-3′,
antisense 5′-GCCTTCTGCACCAGGTAGTT-3′) and restriction digest finger-
printing. The final construct selected for PC3 transfection was validated by
sequencing at the Center for Genome Research and Bioinformatics at the
Oregon State University (sense 5′-GCTAGGCCCGAATGTCGTTA-3′, antisense
5′-GCCTTCTGCACCAGGTAGTT-3′, antisense 5′-ATCTGAGAGCGGCCG
CCACGGCCACAGCCCTGAACG-3′). The final construct was found to contain
the SUV39H1 RefSeq coding sequence (NM_003173.3).
Transient transfection of PC3 cells
PC3 cells were grown to 70–80% confluence in six-well plates and
transfected with pCMV6-AC-GFP or pCMV6-SUV39H1 plasmid using
Lipofectamine 2000 according to the manufacturer’s recommendations
(Invitrogen). Briefly, growth media was replaced with unsupplemented
Dulbecco’s modified Eagle’s medium before transfection. Cells were
transfected with 5 μg plasmid per well and allowed to rest for 12 h. Media
was then replaced with growth media and cells allowed to recover for 24 h
before beginning treatments.
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